New trial tests stronger chemo to spare rectal cancer patients from surgery
NCT ID NCT07472868
Summary
This study aims to see if a more intensive three-drug chemotherapy regimen (FOLFOXIRI) works better than a standard two-drug regimen (CAPOX/FOLFOX) for patients with high-risk rectal cancer that hasn't spread. Both groups will also receive standard chemoradiation and may have surgery or enter a careful monitoring program. The main goal is to see if the stronger chemo leads to more patients having their tumors disappear completely, which could allow them to avoid major surgery and preserve their bowel function.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED RECTAL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Catharina Hospital Eindhoven
Eindhoven, North Brabant, 5623 EJ, Netherlands
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.